SCHEMBL7073263

SCHEMBL7073263

c1ccc(C2CSc3ccccc3C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
GRIN2B Q13224 4/20 0.40
PIM1 P11309 1/20 0.39
FLT3 P36888 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
CYP19A1 P11511 1/20 0.37
SLC18A3 Q16572 3/20 0.36
P2RX7 Q99572 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
PRKACA P17612 1/20 0.36
LTK P29376 1/20 0.36
GRK5 P34947 1/20 0.36
KDR P35968 1/20 0.36
MAP2K2 P36507 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31490454 0.74 GAA (0.56) GRIN2BPIM1FLT3GAAMAPT
SCHEMBL4742061 0.74 GAA (0.56) GRIN2BPIM1FLT3GAAMAPT
SCHEMBL10781695 0.74 ALDH1A1 (0.41) KMT2AMEN1NPC1MAPTRYR2
SCHEMBL11178198 0.74 MAPT (0.52) KMT2AMEN1GAAMAPTSLC18A3
SCHEMBL19871777 0.73
SCHEMBL30873011 0.72 MAPT (0.45) KMT2AMEN1NPC1MAPTCYP19A1
SCHEMBL10585357 0.72 RYR2 (0.37) KMT2AMEN1NPC1GAARYR2
SCHEMBL6444678 0.72 RYR2 (0.37) KMT2AMEN1NPC1GAAMAPT
SCHEMBL8822493 0.72 PLAU (0.45) KMT2AMEN1NPC1GAASIGMAR1
Ammonia Solution, Strong SCHEMBL8090454 0.72 GAA (0.54) GRIN2BPIM1FLT3GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030065008-A1 Selective estrogen receptor modulators in combination with estrogens ENDORECHERCHE, INC. 2003-04-03 US claimed
US-20020198179-A1 Selective estrogen receptor modulators in combination with estrogens ENDORECHERCHE, INC. 2002-12-26 US claimed
EP-1251855-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS Endorecherche, Inc. (CA) 2002-10-30 EP claimed
WO-2001054699-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS ENDORECHERCHE, INC. (CA) 2001-08-02 WO claimed
US-4801593-A VIRICIDE FOR RHINITIS VIRUS CONTAINING 2-PHENYLTETRALIN DERIVATIVE BURROUGHS WELLCOME CO. (US) 1989-01-31 US disclosed
EP-0025598-B1 THE USE OF 2-PHENYLTETRALIN DERIVATIVES, OR HETEROCYCLIC ANALOGUES, IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM THE WELLCOME FOUNDATION LIMITED (GB) 1984-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065008-A1 Selective estrogen receptor modulators in combination with estrogens ESR1, BRCA1, KISS1R KMT2A 691/4885MEN1 54/4885NPC1 1261/4885
US-20020198179-A1 Selective estrogen receptor modulators in combination with estrogens KISS1R, ESR1, BRCA1 KMT2A 716/4885MEN1 48/4885NPC1 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.